# Novosteo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novosteo

- Industry: Pharmaceuticals
- Headquarters: West Lafayette, US
- Website: www.novosteo.com
- Total disclosed funding: $6.1M
- Latest round: Series A (Dec 29, 2020)
- Investors on record: 5

## About

Novosteo Inc. operates within the health and wellness sector, focusing on innovative products designed to improve bone health and musculoskeletal function through advanced dietary supplements.Founded in 2017 in West Lafayette, Indiana, Novosteo Inc. develops solutions for bone health. The company has received a total of USD 5.60 mn across several funding rounds, with the latest being a Series A round on May 10, 2022, led by Kairos Ventures and joined by BioCrossroads, Elevate Ventures, Purdue Research Foundation, among others. The founders of the company are Philip Low and Stewart Low, with Bill Boyle serving as CEO.Novosteo specializes in innovative solutions within the health and wellness sector, primarily focusing on products designed to enhance bone health and overall musculoskeletal function. Their core offerings include a range of dietary supplements that utilize advanced formulations aimed at improving calcium absorption and promoting bone density. These products cater to end users at risk of osteoporosis and other bone-related conditions, including older adults and individuals with specific nutritional needs. Novosteo's products have been launched within the last few years and are targeted at health-conscious consumers across North America and Europe, where market demand for preventive health solutions is on the rise. The company's clientele includes health practitioners, wellness stores, and direct consumers seeking effective nutritional support.Novosteo generates revenue through a direct-to-consumer model as well as partnerships with health and wellness retailers. The company structures its transactions primarily through subscription plans that allow customers to receive regular shipments of their flagship dietary supplements. These subscription services provide a steady revenue stream while ensuring customer retention through convenience and tailored product delivery. Additionally, Novosteo collaborates with various healthcare practitioners, who recommend its products to patients, thereby expanding its market reach. The pricing structure for their offerings is designed to remain competitive within the dietary supplement market, delivering value to both consumers and retail partners.Following the acquisition of Novosteo Inc. by Cortexyme, Inc. in May 2022, the focus will be on expanding the drug development pipeline into rare disease indications with the addition of NOV004, a bone-targeting molecule designed to accelerate fracture repair, including in patients with osteogenesis imperfecta. Plans are underway to launch new products designed for enhanced bone health, targeting health-conscious markets in North America and Europe by mid-2023. The recent funding will support these initiatives, bolstering research and development efforts to strengthen their product offerings.

## Funding rounds

- Series A, Dec 29, 2020, $5.6M — BioCrossroads, Elevate Ventures, Kairos Ventures, Purdue Research Foundation
- Seed, Aug 8, 2019, $0.5M — Research Bridge Partners

## Investors

- Research Bridge Partners (https://capitalatlas.ai/funds/research-bridge-partners) — Seed
- BioCrossroads (https://capitalatlas.ai/funds/biocrossroads) — Series A
- Elevate Ventures (https://capitalatlas.ai/funds/elevate-ventures) — Series A
- Kairos Ventures (https://capitalatlas.ai/funds/kairos-ventures) — Series A
- Purdue Research Foundation — Series A